Human Placental Derived Stem Cell
DrugInfusions of thawed HPDSC to be given following UCB infusion.
Other names: HPDSC
NCT Number: NCT01586455
The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.
Looking for future studies?
Notify Me0 year–55 year
All sexes
Interventional
Phase 1
Children's Hospital Colorado, Denver, Colorado, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Infusions of thawed HPDSC to be given following UCB infusion.
Other names: HPDSC
Time frame: 100 days
to evaluate the safety of human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells in patients with malignant and non-malignant diseases.
Time frame: 1 year
donor chimerism will be assessed at set timepoints
Time frame: 1 year
Time frame: 100 days and 180 days
Time frame: 100 days and 180 days
Time frame: 1 year
New York Medical College
Other
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Acronym: HPDSC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05687474
3-Hydroxy 3-Methyl Glutaric Aciduria, 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency
Liège, Wallonia, Belgium
View Trial DetailsNCT05619900
Brain Diseases, Brain Diseases, Metabolic
San Francisco, California, United States
View Trial DetailsNCT00176917
Bone Diseases, Bone Diseases, Metabolic
Minneapolis, Minnesota, United States
View Trial DetailsNCT06036693
Brain Diseases, Brain Diseases, Metabolic
Angers, France
View Trial Details